Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
CRMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.61 - $13.85
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.90M
Market Cap
$464.75M
Enterprise Value$447.05M
Total Cash (Recent Filing)$35.26M
Total Debt (Recent Filing)$631.39K
Price to Earnings (P/E)―
Beta1.81
Next Earnings
May 08, 2025EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding65,181,770
10 Day Avg. Volume1,544,702
30 Day Avg. Volume1,902,629
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)53.99
Price to Cash Flow (P/CF)-12.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.10
Enterprise Value/Ebitda-23.69
Forecast
1Y Price Target
$15.75Price Target Upside109.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCorMedix announced preliminary 1Q25 financial results with both revenue and adjusted EBITDA ahead of consensus estimates.
Market OpportunitiesTotal Parenteral Nutrition (TPN) represents a sizable total addressable market and expansion opportunity for DefenCath, which could be an underappreciated value driver.
Product AdoptionDefenCath launch continues to outperform at mid-sized dialysis operators, reinforcing robust adoption.
Bears Say
Contract NegotiationsNegotiations with the other LDO (DaVita) appear to be at a standstill.
Sales Expectations2Q25 sales are expected to dip to $17MM-$27MM, which is lower than expected.
Stock PerformanceCRMD shares are under pressure, down approximately 26%, following their 4Q24 earnings update.
---
Ownership Overview
2.30% Insiders
10.39% Mutual Funds
9.23% Other Institutional Investors
67.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $3.61 and its highest was $13.85 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is $464.75M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is May 08, 2025 which is in 21 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Mar 25, 2025. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.132 by $0.088.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is 0.25.
How many shares outstanding does Cormedix have?
Cormedix has 65,181,770 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of $0.22 in its last earnings report, beating expectations of $0.132. Following the earnings report the stock price went down -31.848%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in CRMD
---
Cormedix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (109.44% Upside)
$15.75 (109.44% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.54%
12-Months-Change
Fundamentals
Return on Equity
-23.17%
Trailing 12-Months
Asset Growth
44.83%
Trailing 12-Months
Company Description
Cormedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
---
CRMD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
CorMedix reported a strong financial performance with record-breaking revenue and profitability in Q4 2024, driven by success in the outpatient segment and growth in the inpatient segment. However, challenges such as anticipated net price erosion, delayed LDO implementation, increased operating expenses, and slower progress with expanding the customer base present potential hurdles. Overall, the highlights of financial growth and strategic progress are significant, but the lowlights indicate some critical areas needing attention.Read More>---
CRMD Stock 12 Month Forecast
Average Price Target
$15.75
▲(109.44% Upside)
Technical Analysis
Akebia Therapeutics
―
Kura Oncology
―
Urogen Pharma
―
Bicycle Therapeutics
―
Opthea Limited Sponsored ADR
―
Best Analysts Covering CRMD
1 Year
1 Year Success Rate
15/25 ratings generated profit
1 Year Average Return
+25.68%
reiterated a buy rating 10 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +25.68% per trade.
---